Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Discovery Communications (DISCA) Lags Q2 Earnings and Revenue Estimates

2018-08-07 zacks
Discovery Communications (DISCA - Free Report) just came out with quarterly earnings of $0.66 per share, missing the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.68 per share a year ago. These figures are adjusted for non-recurring items.
DISCB DISCA AMT DISCK NHI BCRX DISC GTLS

2
Facts to Know Ahead of News Corporation's (NWSA) Q4 Earnings

2018-08-06 zacks
News Corporation (NWSA - Free Report) is slated to report fourth-quarter fiscal 2018 results on Aug 9. The company outperformed the Zacks Consensus Estimate in all the trailing four quarters by an average of 79.6%. In the last reported quarter, this diversified media conglomerate delivered a positive earnings surprise of 20%. Let’s see how things are shaping up prior to this announcement. Which Way Are Top & Bottom-Line Estimates Headed? The Zacks Consensus Estimate for the quarter under review stands at 6 cents, reflecting a year-over-year decline of 45.
GJV FOX MKGAF DISCB DISCA NWSA DISCK BGSF AMCX MKGAY NWS FOXA DISC

0
ProSiebenSat.1 Media's (PBSFY) CEO Max Conze on Q2 2018 Results - Earnings Call Transcript

2018-08-04 seekingalpha
Good morning, ladies and gentlemen. Welcome to the Q2 and H1 2018 results call of ProSiebenSat.1 Media SE. This conference is being recorded. Today's call is hosted by Ms. Stefanie Rupp-Menedetter. Please go ahead.
DISCB DISCA NYTAB DISCK PBSFY DISC

0
Can Discovery (DISCA) Keep the Earnings Surprise Streak Alive?

2018-08-03 zacks
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Discovery Communications (DISCA - Free Report) , which belongs to the Zacks Broadcast Radio and Television industry, could be a great candidate to consider.
DISCB DISCA DISCK DISC

19
Viacom Stock Is Pretty Cheap, But Not Cheap Enough Yet

2018-07-31 investorplace
I certainly understand the appeal of Viacom (NASDAQ:VIA,VIAB) stock. Viacom B stock (which is much cheaper than the VIA Class A issue), the stock trades at just 6.5x 2019 consensus EPS. That still is probably too much to pay for Viacom stock.
CBS VIA DISCB DISCA CBS.A CCV CMCSA TWX NFLX CCZ DISCK TWC CBS.WD GTN.A GTN T AMCX CCV.CL CPV CMCSK DIS DISC

142
SA Interview: Taking Advantage Of Short-Term Volatility With Chad Brand

2018-06-24 seekingalpha
Chad Brand is the founder and President of Peridot Capital Management, an independent registered investment advisor.
DISCB DISCA IPIC NFLX DISCK CVS SRG AMZN AMCX KSS DISC

26
Oprah Winfrey, worth $4 billion, now one of the world's richest people

2018-06-21 cnbc
Media mogul Oprah Winfrey just became one of the 500 richest people in the world. Since January 1, her net worth has grown by over $420 million and now totals $4.02 billion, according to the Bloomberg Billionaires Index.
DISCB DISCA DISCK DISC

217
Nasdaq Composite Closes at Record High: 5 Top-Ranked Picks

2018-06-15 zacks
On Jun 14, the tech-heavy Nasdaq Composite index scaled a fresh high at closing. Yesterday’s rally can be attributed to strong showing by media, telecom and tech stocks fueled by market anticipation of mega merger deals. This also highlights the gradual fading of investors’ apprehensions regarding the trade and geopolitical issues, which was the primary reason behind severe market volatility in the last three months.
FOX DISCB DISCA TWX DISCK TWC CHTR CMTL MU MLNX SPG NTAP FOXA DIS DISC

248
With or Without Time Warner, AT&T Stock Isn't Worth Buying | InvestorPlace

2018-06-13 investorplace
The acquisition of Time Warner Inc (NYSE:TWX) by AT&T Inc. (NYSE:T) appears to be a go. And the approval of the AT&T-TWX merger, announced Tuesday afternoon, already is reverberating through the market.
DISCB DISCA CCV TWX CCZ DISCK AMCX VIAB AET CMCSK DIS DISC CBS VIA FOX TMUSP CBS.A TMUS CMCSA TWC CBS.WD S T CCV.CL CPV FOXA ESRX

29
Corporate round-up: Aegon Life appoints Saba Adil as Chief Operating Officer

2018-06-11 moneycontrol
Aegon Life Insurance has appointed Saba Adil as the new chief operating officer, effective May 1.
HYUO DISCB DISCA HYUP DISCK HYUD DISC

51
Discovery Communications (DISCA) Down 5.7% Since Earnings Report: Can It Rebound?

2018-06-07 zacks
A month has gone by since the last earnings report for Discovery Communications, Inc. (DISCA - Free Report) . Shares have lost about 5.7% in that time frame.
SNI DISCB DISCA ENL DISCK CRAI ENDP DISC

87
Palatin shares up 9% premarket

2018-06-04 marketwatch
Palatin Technologies Inc. shares surged 9% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has accepted the new drug application for bremelanotide, a treatment for female sexual desire disorder. The NDA was filed by Amag Pharmaceuticals Inc. , Palatin's exclusive North America licensee, in March. The goal date for completion of the review is March 23, 2019. If approved, bremelanotide would be the first and only treatment for hypoactive sexual desire disorder (HSDD) in pre-menopausal women.
VRTX AMAG DISCB DISCA PTN NYTAB DISCK FOSL DISC

122
How Facebook Let Gadgets Tap Your Data: DealBook Briefing - The New York Times

2018-06-04 nytimes
The technology giant struck data-sharing partnerships with at least 60 device makers — including Amazon, Apple, BlackBerry, Microsoft and Samsung — over the last decade. The company claimed that those deals were supposed to make it easier for people to use Facebook before its app was widely available on smartphones. But an NYT investigation found that the deals provided wide-ranging access to user data, and that many arrangements still exist, even though Facebook said that it had cut such off third-party access in 2015.
DISCB DISCA PANW NYTAB DISCK SNAP DISC

26
Orange aiming to merge video arm with Altice Studio - Le Figaro

2018-05-31 reuters
PARIS (Reuters) - Orange (ORAN.PA), France’s biggest telecoms operator, is looking to merge its Orange Cinema Series (OCS) arm with Altice Studio (ATCA.AS) to create a new business big enough to challenge the likes of Netflix (NFLX.O), Le Figaro newspaper reported.
DISCB DISCA DISCK DISC

257
Zero Cost Of Capital

2018-05-31 seekingalpha
Today’s strange occurrence has been called a “zero cost of capital” and it rhymes with what happened in 1999-2000.
DISCB DISCA WBA NFLX DISCK TGT JWN AMZN TSLA RNG NTNX DISC ETSY

Related Articles

REPH: Recro Pharma Analysis and Research Report

9h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

9h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

10h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 25470F302